The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats

被引:11
作者
Ortmann, S
Kampe, J
Gossel, M
Bickel, M
Geisen, K
Jähne, G
Lang, HJ
Klaus, S
机构
[1] German Inst Human Nutr Potsdam, Grp Energy Metab, D-14458 Nuthetal, Germany
[2] Aventis Pharma Deutschland GmbH, DG Metab Dis, Frankfurt, Germany
[3] Aventis Pharma Deutschland GmbH, DI&A Chem Med Chem, Frankfurt, Germany
[4] Inst Zoo & Wildlife Res, Berlin, Germany
来源
OBESITY RESEARCH | 2004年 / 12卷 / 08期
关键词
anorectica; energy expenditure; adipose tissue; thermogenesis; body temperature;
D O I
10.1038/oby.2004.163
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the effect of acute and chronic administration of a new food intake-reducing compound (HMR1426) with novel mode of action (retardation of gastric emptying) on body weight development, food intake, and energy metabolism in rats. Research Methods and Procedures: Adult male Shoe-Wistar rats were implanted with transponders allowing registration of body temperature (T-b) and locomotor activity. HMR1426 (10 or 50 mg/kg) was given orally, and acute (8 hours) and chronic (15 days) effects were measured on food intake, Tb, activity, total energy expenditure (indirect calorimetry), and epididymal adipose tissue mass. The effect of chronic treatment was compared with the effect of sibutramine (10 mg/kg). Results: HMR1426 (50 mg/kg) caused an acute and chronic decrease of food intake. There was no effect on the level and daily pattern of total energy expenditure, T-b, and locomotor activity. Respiratory quotient was acutely decreased by HMR1426 due to reduced food intake. Chronic treatment with HMR1426 decreased weight gain by 31% and epididymal white fat by 24%. Sibutramine caused a respective reduction of 48% and 35%. Energy efficiency was not affected by HMR1426 in contrast to sibutramine, which reduced energy efficiency and transiently increased activity. Discussion: HMR1426 showed an anorectic potential in rats and decreased body weight and fat mass. This was achieved solely by reducing food intake without influencing overall energy expenditure or behavior suggesting a peripheral mode of action. Thus, HMR1426 can be considered a potential new drug for obesity treatment.
引用
收藏
页码:1290 / 1297
页数:8
相关论文
共 19 条
[1]   Characterization of the effects of pancreatic polypeptide in the regulation of energy balance [J].
Asakawa, A ;
Inui, A ;
Yuzuriha, H ;
Ueno, N ;
Katsuura, G ;
Fujimiya, M ;
Fujino, MA ;
Niijima, A ;
Meguid, MM ;
Kasuga, M .
GASTROENTEROLOGY, 2003, 124 (05) :1325-1336
[2]   Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats [J].
Bickel, M ;
Gossel, M ;
Geisen, K ;
Jaehne, G ;
Lang, HJ ;
Rosenburg, R ;
Sandow, J .
INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (02) :211-221
[3]   Drug Treatment of Obesity [J].
Bray G.A. .
Reviews in Endocrine and Metabolic Disorders, 2001, 2 (4) :403-418
[4]   Sibutramine produces dose-related weight loss [J].
Bray, GA ;
Blackburn, GL ;
Ferguson, JM ;
Greenway, FL ;
Jain, AK ;
Mendel, CM ;
Mendels, J ;
Ryan, DH ;
Schwartz, SL ;
Scheinbaum, ML ;
Seaton, TB .
OBESITY RESEARCH, 1999, 7 (02) :189-198
[5]   Anti-obesity drugs: a critical review of current therapies and future opportunities [J].
Clapham, JC ;
Arch, JRS ;
Tadayyon, M .
PHARMACOLOGY & THERAPEUTICS, 2001, 89 (01) :81-121
[6]   Thermogenic effects of sibutramine and its metabolites [J].
Connoley, IP ;
Liu, YL ;
Frost, I ;
Reckless, IP ;
Heal, DJ ;
Stock, MJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (06) :1487-1495
[7]   Sibutramine: its mode of action and efficacy [J].
Finer, N .
INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 (Suppl 4) :S29-S33
[8]   Long-term pharmacotherapy of obesity 2000 - A review of efficacy and safety [J].
Glazer, G .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (15) :1814-1824
[9]  
GOSSEL M, 2001, OBES RES S, V9, pPG72
[10]   Orlistat - Selective inhibition of caloric absorption can affect long-term body weight [J].
Hauptman, J .
ENDOCRINE, 2000, 13 (02) :201-206